Board to approve quarterly and half-year results on November 2

Revenue growth above 20%Profit growth above 25%EBITDA margin expansionResults View source PDF Explain this filing

AKUMS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.3%Reaction day

₹717.95

prior close

₹717.60

announcement price

After-mkt

timing

Nifty Microcap 250market+0.7%+2.6% vs market

Pharmaceuticals peers, median of 171sector+0.4%+2.9% vs sector

On the reaction day the stock moved 2.6 pts more than Nifty Microcap 250 and 2.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.3

15m

+0.3

30m

+0.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.3+0.7+2.6+0.4+2.9

Next day

+2.4-1.9+4.2-0.7+3.0

+2.3-0.4+2.7-0.5+2.8

+5.6-0.2+5.8-0.1+5.7

+4.4+2.0+2.4+0.7+3.8

+3.7+3.1+0.6+1.8+2.0

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The board will meet on November 2, 2026, to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. Trading in the company's shares remains closed and will reopen 48 hours after the results are declared.

Likely market impact

No financial figures were disclosed, so there is no immediate evidence of any change in earnings or financial health.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹1,342 Cr	₹1,018 Cr	+31.9%
Operating profit	₹125.8 Cr	₹33.31 Cr	+277.8%
Profit after tax	₹114.6 Cr	₹42.70 Cr	+168.3%
EBITDA margin	14.5%	9.3%	+5.2 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.